Milk thistle's active components silybin and isosilybin : Novel inhibitors of pxr-mediated cyp3a4 induction

Drug Metabolism and Disposition

Volumn 41, Issue 8, 2013, Pages 1494-1504

  Mooiman, Kim D ^a   Maas Bakker, Roel F ^a   Moret, Ed E ^b   Beijnen, Jos H ^a,c   Schellens, Jan H M ^a,d   Meijerman, Irma ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Chemical Biology   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

A 792611; ASCORBIC ACID; BETA CAROTENE; CYANOCOBALAMIN; CYTOCHROME P450 3A4; ECHINACEA PURPUREA EXTRACT; ERLOTINIB; FLAVONOID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; HYPERICUM PERFORATUM EXTRACT; ISOSILYBIN; KETOCONAZOLE; PACLITAXEL; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; PYRIDOXINE; RIFAMPICIN; SABAL EXTRACT; SILIBININ; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG; VALERIAN;

ALTERNATIVE MEDICINE; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG INTERACTION; DRUG PROTEIN BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; SILYBUM MARIANUM;

BINDING, COMPETITIVE; CELL LINE, TUMOR; COMPLEMENTARY THERAPIES; CYTOCHROME P-450 CYP3A; ENZYME INDUCTION; HUMANS; MILK THISTLE; MOLECULAR DOCKING SIMULATION; RECEPTORS, STEROID; SILYMARIN;

EID: 84880659900     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.050971     Document Type: Article

References (30)

1. Anzenbacher P and Anzenbacherová E (2001) Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747.
2. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, and Ekins S (2009) Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res 26:1807-1815.
3. Chen Y, Tang Y, Robbins GT, and Nie D (2010) Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther 334:999-1008.
4. Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, and Redinbo MR (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125-1134.
5. Degoey DA, Grampovnik DJ, Flentge CA, Flosi WJ, Chen HJ, Yeung CM, Randolph JT, Klein LL, Dekhtyar T, and Colletti L, et al. (2009) 2-Pyridyl P19-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects. J Med Chem 52:2571-2586.
6. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, and Lee T, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24: 1999-2012.
7. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, and Sinz M, et al. (2007) Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592-603.
8. Gatti G and Perucca E (1994) Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 32:614-617.
9. Gupta D, Lis CG, Birdsall TC, and Grutsch JF (2005) The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 13:912-919.
10. Harmsen S, Koster AS, Beijnen JH, Schellens JH, and Meijerman I (2008) Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos 36:1166-1171.
11. Harmsen S, Meijerman I, Beijnen JH, and Schellens JH (2009) Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 64:35-43.
12. Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, and Kim RB (2008) A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500-507.
13. Kerbusch T, Huitema AD, Ouwerkerk J, Keizer HJ, Mathǒt RA, Schellens JH, and Beijnen JH (2000) Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br J Clin Pharmacol 49:555-561.
14. Krieger E, Darden T, Nabuurs SB, Finkelstein A, and Vriend G (2004) Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins 57: 678-683.
15. Kroll DJ, Shaw HS, and Oberlies NH (2007) Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6:110-119.
16. Lau AJ, Yang G, Yap CW, and Chang TK (2012) Selective agonism of human pregnane X receptor by individual ginkgolides. Drug Metab Dispos 40:1113-1121.
17. Lee JI, Narayan M, and Barrett JS (2007) Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 845:95-103.
18. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
19. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, and Gilbert D, et al. (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804.
20. McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, and Ellis GK (2004) Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12:454-462.
21. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and and empirical binding free energy function. J Comput Chem 19:1639-1662.
22. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, and Vilarem MJ (2003) The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619:243-253.
23. Shukla SJ, Nguyen DT, Macarthur R, Simeonov A, Frazee WJ, Hallis TM, Marks BD, Singh U, Eliason HC, and Printen J, et al. (2009) Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev Technol 7:143-169.
24. Sparreboom A, Cox MC, Acharya MR, and Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489-2503.
25. Tascilar M, de Jong FA, Verweij J, and Mathijssen RH (2006) Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 11:732-741.
26. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, and Gelderblom H (2005) Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-7806.
27. Watkins RE, Davis-Searles PR, Lambert MH, and Redinbo MR (2003) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331: 815-828.
28. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, and Redinbo MR (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329-2333.
29. Werneke U, Earl J, Seydel C, Horn O, Crichton P, and Fannon D (2004) Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90:408-413.
30. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, and Redinbo MR (2007) Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem 15:2156-2166.